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The modifier of Min 2 (Mom2) locus: Embryonic
lethality of a mutation in the Atp5a1 gene suggests
a novel mechanism of polyp suppression
Amy A. Baran,1,4 Karen A. Silverman,1,4,6 Joseph Zeskand,1,7 Revati Koratkar,1
Ashley Palmer,1,8 Kristen McCullen,2 Walter J. Curran Jr,1 Tina Bocker Edmonston,3
Linda D. Siracusa,1,5 and Arthur M. Buchberg1,5,9
1Kimmel Cancer Center, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA;
2Department of Obstetrics and Gynecology, Thomas Jefferson University, Jefferson Medical College, Philadelphia, Pennsylvania
19107, USA; 3Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Jefferson Medical College,
Philadelphia, Pennsylvania 19107, USA
Inactivation of the APC gene is considered the initiating event in human colorectal cancer. Modifier genes that
influence the penetrance of mutations in tumor-suppressor genes hold great potential for preventing the
development of cancer. The mechanism by which modifier genes alter adenoma incidence can be readily studied in
mice that inherit mutations in the Apc gene. We identified a new modifier locus of ApcMin-induced intestinal
tumorigenesis called Modifier of Min 2 (Mom2). The polyp-resistant Mom2R phenotype resulted from a spontaneous
mutation and linkage analysis localized Mom2 to distal chromosome 18. To obtain recombinant chromosomes for use
in refining the Mom2 interval, we generated congenic DBA.B6 ApcMin/+, Mom2R/+ mice. An intercross revealed that
Mom2R encodes a recessive embryonic lethal mutation. We devised an exclusion strategy for mapping the Mom2 locus
using embryonic lethality as a method of selection. Expression and sequence analyses of candidate genes identified a
duplication of four nucleotides within exon 3 of the  subunit of the ATP synthase (Atp5a1) gene. Tumor analyses
revealed a novel mechanism of polyp suppression by Mom2R in Min mice. Furthermore, we show that more adenomas
progress to carcinomas in Min mice that carry the Mom2R mutation. The absence of loss of heterozygosity (LOH) at
the Apc locus, combined with the tendency of adenomas to progress to carcinomas, indicates that the sequence of
events leading to tumors in ApcMin/+ Mom2R/+ mice is consistent with the features of human tumor initiation and
progression.
[Supplemental material is available online at www.genome.org.]
Colorectal cancer is one of the leading causes of cancer deaths in
the United States (www.cancer.org). The dysregulation of normal
colonic epithelium leads to the formation of adenomas, which
are considered a prerequisite to progression to carcinoma (Fodde
et al. 2003). This multistep process involves interactions between
the genome and the gut environment, leading to mutations and
epigenetic changes in oncogenes and/or tumor suppressor genes
(Kinzler and Vogelstein 1996; Ilyas et al. 1999; Gregorieff and
Clevers 2005). However, the variation in penetrance of heredi-
tary forms of cancer has emphasized the impact of tumor-
modifier genes that can influence individual susceptibility to
cancer by either enhancing or suppressing the initiation, growth,
and/or progression of tumor cells. Due to environmental and
genetic heterogeneity in the human population, it has been dif-
ficult to identify tumor modifier loci in humans. Therefore, com-
plex trait analysis in experimental mouse crosses is a powerful
approach to genetically dissect multigenic diseases (Moore and
Nagle 2000; Threadgill et al. 2002; Siracusa et al. 2004).
The mapping, identification, and characterization of genes
influencing tumor susceptibility has been facilitated by the use of
mammalian models (Mao and Balmain 2003). Inbred strains of
mice that differ in their susceptibility to various types of solid
tumors and leukemias have been instrumental in uncovering loci
that affect tumor risk (Dragani 2003; Mao and Balmain 2003).
Tumor susceptibility genes may act cell autonomously within the
tumor lineage, or may act in a non-cell autonomous fashion
within the microenvironment leading to tumor formation (De-
mant 2003). Genomic differences among inbred strains of mice
are being exploited to limit the regions containing the causative
allelic variants and ultimately identify the genes responsible (Sir-
acusa et al. 2004).
Modifier genes affect the phenotype caused by a mutation
in another gene. A classic example of such a system with respect
to tumorigenesis involves loci called the Modifiers of Min (Mom),
which influence the intestinal tumor phenotype of Min mice
carrying a mutation in the adenomatous polyposis coli gene
(ApcMin) (Dietrich et al. 1993). To date, four Mom loci have been
identified (Mom1, Mom2, Mom3, and Mom6) (Dietrich et al. 1993;
Cormier et al. 2000; Silverman et al. 2002; Haines et al. 2005), but
only one gene has, as yet, been proven to be responsible for
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altering the Mom phenotype otherwise dictated by a mutation in
the Apc gene (MacPhee et al. 1995; Cormier et al. 1997).
Our laboratory identified the Mom2 locus in hybrid off-
spring derived from a cross involving DBA/2J (DBA) and C57BL/
6J (B6) ApcMin/+ mice (Silverman et al. 2002). We initially local-
ized Mom2 to a 14-cM region on distal chromosome 18, between
the D18Mit186 and D18Mit213 markers. Inheritance patterns of
the Mom2 phenotype suggested that the resistant Mom2 allele
(Mom2R) arose from a spontaneous mutation in a B6 ApcMin/+
progenitor. On both inbred strain backgrounds, one Mom2R allele
decreases small intestinal polyp number and colon polyp inci-
dence by ∼90% (Silverman et al. 2002); thus, Mom2R has signifi-
cantly greater effects on polyp multiplicity than Mom1R, which,
when present in one copy, decreases small intestinal polyp num-
ber and size by ∼50% (Cormier et al. 1997; Silverman et al. 2002).
The presence of the Mom1 locus, in addition to other un-
linked modifiers of intestinal polyp formation in the mouse ge-
nome, indicated the necessity to control genetic background for
further studies of the Mom2 locus. Therefore, we generated con-
genic mice carrying the Mom2R allele on both the DBA and B6
inbred strain backgrounds (Silverman et al. 2003). The Mom2
locus was limited to <10 cM by genotyping progeny and com-
paring small intestinal polyp multiplicity with the distribution of
recombinant breakpoints (Silverman et al. 2003).
We now report that intercrosses of DBA.B6 Mom2R/+ animals
produced no offspring homozygous for the resistant Mom2R al-
lele. To facilitate the genetic dissection of Mom2, we established
crosses between DBA.B6 Mom2R/+ animals and Mus musculus cas-
taneus (CAST) mice. The increase in polymorphic markers,
coupled with making use of the Mom2R homozygous lethal phe-
notype, provided an exclusion mapping strategy that refined the
Mom2 interval to <1 Mb. Our finding of a duplication that dis-
rupts the Atp5a1 gene, a gene required for oxidative metabolism,
provided testable hypotheses for both the modifier effect on
ApcMin-induced tumorigenesis and the phenotype of recessive
embryonic lethality.
Results
Intercrosses of congenic DBA.B6 Mom2R/+ mice fail to generate
homozygous Mom2R progeny
To maintain the Mom2R mutation, as well as to obtain recombi-
nant chromosomes for use in the refinement of the Mom2 locus,
we generated congenic animals carrying the C57BL/6J (B6)
Mom2R allele on the DBA/2J (DBA) genetic background by se-
quential backcrosses (Silverman et al. 2003). Offspring were
genotyped for the ApcMin mutation and genotyped for the Mom2
locus using the Mom2 flanking markers D18Mit80 and
D18Mit213 (Silverman et al. 2003). Progeny were selected that
carried the resistant Mom2 allele (Mom2R), but did not carry the
ApcMin mutation. DBA.B6 Mom2R/+ animals from the N4–N5
backcross generations were intercrossed to generate animals ho-
mozygous for the resistant Mom2R allele. Surprisingly, our inter-
cross resulted in 36 F2 Mom2
R/+ heterozygotes and 25 F2 wild-type
Mom2+/+ progeny, with no F2 animals homozygous for the
Mom2R allele. 2 analysis indicated that the expected Mendelian
distribution of 1:2:1 was significantly different (P < 0.001) from
the observed distribution of F2 animals obtained from our
Mom2R intercross (1.4:1). In addition, the observed 1.4:1
(Mom2R/+:Mom2+/+) ratio was not significantly different (P = 0.2)
from a ratio of 2:1 (Mom2R/+:Mom2+/+), suggesting that the
Mom2R allele is a recessive embryonic lethal mutation. Additional
experiments have confirmed that homozygous Mom2R mice are
never born (see below).
The Mom2R locus encodes a recessive embryonic lethal
mutation
We tested the hypothesis that the mutant Mom2R allele may im-
pair the normal function of either oocytes or sperm by determin-
ing whether Mom2R could be equally inherited from a heterozy-
gous Mom2R/+ mother or a heterozygous Mom2R/+ father. Table 1
shows the crosses, number of mating cages, and genotypes of the
resulting progeny. In two of the four backcrosses, offspring could
inherit a Mom2R allele from their heterozygous mother, whereas
in the remaining two backcrosses, offspring could inherit a
Mom2R allele from their heterozygous father. Analysis of the dis-
tribution of Mom2R/+ versus Mom2+/+ offspring by the 2 test re-
vealed no significant differences in inheritance patterns between
the mutant Mom2R and wild-type Mom2+ loci (Table 1). There-
fore, the function of oocytes and sperm do not appear to be
impaired by the presence of the Mom2R mutation. The data sug-
gest that the death of Mom2R/R embryos occurs sometime after
fertilization, but before birth.
To investigate the developmental stage of embryonic lethal-
ity, timed pregnancies from intercrosses of DBA.B6 Mom2R/+ mice
were established. A total of 41 embryos, which includes embry-
onic tissue from six resorption sites, were obtained from six fe-
males at 12.5 d post coitus (dpc). Genomic DNA from each em-
bryo was genotyped for the Mom2 flanking markers, D18Mit80
and D18Mit213, to distinguish the presence of the B6 Mom2R
locus from the wild-type DBA Mom2+ locus (Silverman et al.
2003). Ten embryos were homozygous for the wild-type DBA
allele at both loci, 24 embryos were heterozygous for the B6 and
DBA alleles at both loci, and seven embryos were single recom-
binants (three embryos were D/B at the D18Mit80 locus and D/D
at the D18Mit213 locus; two embryos were D/D at the D18Mit80
locus and D/B at the D18Mit213 locus; and two embryos were
D/B at the D18Mit80 locus and B/B at the D18Mit213 locus).
None of the 41 embryos were homozygous for B6 alleles at both
the D18Mit80 and D18Mit213 loci, demonstrating that Mom2R/R
embryos die before 12.5 dpc.
Refining the localization of Mom2 by an exclusion mapping
strategy
The proof of embryonic lethality coupled with the ability to de-
tect recombinants in the Mom2 region provided a strategy to
Table 1. The Mom2R allele can be transmitted to offspring from
both female and male parents
Crossa
No. of
mating
cages Mom2+/+ Mom2R/+ 2 P value
DBA.B6 Mom2R/+ B6
ApcMin/+ 6 41 31 1.4 P > 0.05
DBA.B6 ApcMin/+,
Mom2R/+  DBA 6 31 27 0.3 P > 0.05
DBA  DBA.B6
Mom2R/+ 5 50 53 0.1 P > 0.05
DBA  DBA.B6
ApcMin/+, Mom2R/+ 10 88 93 0.1 P > 0.05
The D18Mit80 and D18Mit213 markers were used to distinguish the
presence of the B6 Mom2R locus from the wild-type DBA Mom2+ locus
(Silverman et al. 2003).
aFor each cross, the female is listed first.
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further define the boundaries of the Mom2R locus. To facilitate
the genetic dissection and further refinement of the Mom2 inter-
val, we initiated crosses with CAST/Ei (CAST) mice (Silver 1995).
The CAST subspecies diverged from common laboratory strains
by one to two million years, thus providing genetic diversity to
increase the number of polymorphisms (Silver 1995). Six mating
cages of CAST  DBA.B6 Mom2R/+ animals from the N7–N8 back-
cross generations (Fig. 1A) produced 94 F1 offspring that were
genotyped for the Mom2 region. While all F1 offspring inherited
a CAST allele at each marker, either a DBA allele (Mom2+) or the
B6 allele (Mom2R) could be inherited from the heterozygous
DBA.B6 Mom2R/+ congenic parent. Since the Mom2R mutation
arose on a B6 background, F1 progeny were selected that carried
the B6 allele at both the proximal D18Mit186 and distal
D18Mit213 markers. These [CAST  DBA.B6 Mom2R/+]F1 hybrid
mice were intercrossed to generate F2 progeny that were geno-
typed for D18Mit186 and D18Mit213. Only F2 animals recombi-
nant within the Mom2 interval were subjected to further screen-
ing (Fig. 1B).
We used an exclusion mapping technique for the Mom2
locus based on the lack of Mom2R/R homozygous liveborn prog-
eny from the DBA.B6 Mom2R/+ intercross. Since Mom2R is a reces-
sive embryonic lethal mutation, no animals homozygous for the
B6 Mom2R allele should survive. Therefore, any marker within
the Mom2 region that was homozygous for the B6 allele would be
excluded as being part of the Mom2 locus (Fig. 1B,C). Progeny
from the [CAST  DBA.B6 Mom2R/+]F1 intercross were identified
that were B/B at either the proximal (D18Mit186) or distal
(D18Mit213) markers, and were B/C or C/C at the other, indicat-
ing that a recombination occurred within the Mom2 region (Fig.
1B). Of 536 F2 offspring, 22 were informative recombinants. No
F2 progeny were identified that were B/B at both the D18Mit186
and D18Mit213 markers; 452 nonrecombinant F2 animals
showed a distribution of 159: 293: 0 (C/C: B/C: B/B), with a 1: 1.8
ratio instead of a Mendelian 1:2:1 ratio (2 = 129.4, P < 0.0001),
confirming the recessive embryonic lethality of the Mom2R mu-
tation.
To further dissect the Mom2 locus, the 22 recombinant F2
animals were genotyped for additional markers (Fig. 1C). The
spontaneous mutation that created the Mom2R allele did not ap-
pear to cause a gross deletion, inversion, or large alteration that
affected genes in the region. All markers, with the exception of
D18Mit47 and D18Mit106, were homozygous for B/B alleles in at
least one mouse, thus excluding them from consideration (Fig.
1C). Analysis of recombination breakpoints indicates that the
Mom2 locus must reside between the D18Kcc2 (within the St8sia5
[formerly known as Siat8e] gene) and D18Kcc10 (within the
Slc14a2 gene) markers (Supplemental Table 1).
To further narrow the location of the Mom2 gene, F2 prog-
eny that were heterozygous for the Mom2 region were sequen-
tially intercrossed. F3 offspring were identified that carried cross-
overs between the St8sia5 and Slc14a2 genes. Intercrosses of these
recombinant F3 progeny produced 64 F4 mice that were either
pure CAST or mice that were heterozygous throughout the Mom2
region. No mice that were homozygous for B6 alleles in the Mom2
region were born, consistent with the recessive embryonic lethal-
ity of the Mom2R mutation. These data demonstrated that the
region distal to St8sia5 and proximal to D18Kcc7 (within the
5430411K18Rik gene) contained a recessive embryonic lethal
mutation and excluded both the Slc14a1 and Slc14a2 genes as
candidates (Supplemental Table 1). Based on Build 34 from the
Ensembl database, the Mom2 interval is ∼800 kb in length and
encodes six known genes, one novel gene, one pseudogene, and
one predicted gene (www.ensembl.org/Mus musculus/October
2005).
Figure 1. Exclusion mapping strategy to refine the Mom2 locus. (A)
Based on the observation that the Mom2R locus encodes a recessive em-
bryonic lethal mutation, we devised a strategic intercross of (CAST 
DBA.B6 Mom2R/+)F1 mice to limit the boundaries of the Mom2 locus.
Since mice homozygous for the B6 Mom2R allele (B/B) should not survive,
markers within the Mom2 region that were homozygous for B6 alleles
would be excluded. DBA.B6 Mom2R/+ animals from the N7–N8 genera-
tions were mated to CAST mice. DBA chromosomes are shown in white;
the B6 Mom2R region is shown in black; CAST chromosomes are repre-
sented by diagonal stripes and heterozygotes are shown in gray. The
possible F2 progeny are shown in black boxes; all offspring were geno-
typed for proximal (D18Mit186) and distal (D18Mit213) markers flanking
Mom2 (Silverman et al. 2002, 2003). (B) The number of resulting F2
progeny are shown below the boxes. Nonrecombinant F2 progeny are in
the black box on the left; representative recombinant progeny are in the
boxes to the right. F2 offspring that were B/B at either the proximal
(D18Mit186) or distal (D18Mit213) marker and were B/C or C/C at the
other, indicated the occurrence of a recombination within the Mom2
region. Nonrecombinant CAST DBA.B6 Mom2R animals were uninforma-
tive for linkage analysis. (C) Haplotype analysis of recombinant F2 animals
from the [CAST  DBA.B6 Mom2R/+]F1 intercross. Mapped loci are listed
on the left. Numbers below each column of boxes represent the number
of F2 progeny that fall into each haplotype. F2 progeny were identified
that were B/B at either the proximal or distal marker, and were B/C or C/C
at the other, indicating an informative recombinant within the Mom2
region; these 22 mice were genotyped by PCR for polymorphic markers
within the Mom2 region. This analysis positioned Mom2 between the
D18Mit7 locus and the Slc14a2 gene.
Baran et al.
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Expression analysis and sequencing of genes within the Mom2
region reveals a mutation in the Atp5a1 gene
Based on an early-acting recessive embryonic lethal mutation
at the Mom2 locus, we hypothesized that the mutated gene
would most likely represent a null allele. Therefore, we examined
the expression levels of genes within the Mom2 interval by
real-time PCR. Assays-on-Demand (ABI) provided tests for
Atp5a1, Ccdc5, Loxhd1, Pstpip2, 8030462N17Rik, and St8sia5. To-
tal RNA was isolated from the proximal and distal small intes-
tine and colon of congenic DBA.B6 Mom2R/+ mice along
with control DBA and B6 mice. Of all the genes tested, only
the Atp5a1 gene showed a significant decrease in mRNA levels
compared with that predicted for a DBA  B6 F1 hybrid
(Fig. 2A).
Results of real-time PCR were consistent with the Atp5a1
gene being expressed solely from the DBA allele in the congenic
DBA.B6 Mom2R/+ mice. Therefore, we sequenced each exon of the
Atp5a1 gene from genomic DNA of congenic DBA.B6 Mom2R/+
and B6 Mom2R/+ mice, along with control DBA and B6 mice
(Supplemental Table 2). The results revealed a 4-bp duplication
in the coding region (exon 3), which was present in mice carry-
ing the Mom2R allele and absent in Mom2+/+ controls (Fig. 2B).
This duplication is predicted to cause a frameshift mutation,
which would result in aberrant incorporation of 42 amino acids
followed by a stop codon in exon 4, downstream of the mutation
site (Fig. 2C). If the transcript from the Mom2R allele was equally
stable as from the Mom2+ allele, the predicted mutant mRNA
would be the same size as the wild-type mRNA, and was therefore
not detectable by Northern blot analyses (data not shown). How-
ever, sequencing cDNA generated from Mom2R/+ intestines failed
to identify any mutant Atp5a1 transcripts, suggesting that this
allele does not generate a stable transcript (data not shown). In
addition, sequencing of the flanking Ccdc5 and Pstpip2 genes
showed no differences between Mom2R/+ mice and wild-type
mice (Supplemental Tables 3, 4).
To further cement the relationship between the 4-bp dupli-
cation in the Atp5a1 gene and the Mom2R phenotype, we se-
quenced the original B6 ApcMin/+ father who first transmitted the
Mom2R allele to his progeny (Silverman et al. 2002); results
showed that he indeed carried the mutation. Sequencing of five
Mom2R/+ mice, three from the real-time PCR studies, and the two
F3 parents (see above), further confirmed the presence of the
mutation in mice carrying the Mom2R allele. No polymorphisms
between the DBA and B6 strains in coding regions, untranslated
regions, or splice junctions were found.
We designed a positive/negative PCR-based assay to detect
the presence of the mutated Atp5a1 allele using a forward primer
that incorporated the 4-bp duplication in its sequence (see Meth-
ods). The specificity of the primer ensured that it would only
bind a genomic fragment that contains the mutant Atp5a1 allele.
A PCR fragment of 147 bp was detected if the Atp5a1 duplication
was present, whereas no fragment was produced from the wild-
type allele. Further studies compared the number of polyps in
ApcMin/+ mice carrying the mutated Atp5a1Mom2R allele with those
carrying the wild-type Atp5a1+ allele. Twenty DBA.B6 ApcMin/+
mice were randomly selected from the N7–N16 backcross gen-
erations and genotyped to determine whether they carried mu-
tant or wild-type Atp5a1 alleles. The average polyp number
( SD) for the 10 mice carrying the mutant Atp5a1Mom2R allele
was 9.6  4.8 polyps, whereas the average polyp number ( SD)
for the 10 mice carrying the wild-type Atp5a1+ allele was
78.3 32.9 polyps. Additional offspring have shown an identical
relationship (data not shown). Thus, there is a 100% concordance
between the presence of the mutant Atp5a1 allele and resistance to
ApcMin-induced intestinal polyposis.
Mechanism of protection from polyp development
by the Mom2 locus
The finding of a mutation in the Atp5a1 gene suggested a poten-
tial mechanism, whereby the formation of polyps is inhibited in
the presence of the mutation. Since the Atp5a1 gene is essential
for aerobic respiration (Comelli et al. 1998, 2003; Schnaufer et al.
2005), its absence would result in cell death. This action would be
cell autonomous. B6 ApcMin/+ mice develop polyps along the in-
testinal tract; nearly 100% of polyps that develop in the small
intestine occur by somatic recombination, which results in loss
of heterozygosity (LOH) for the ApcMin mutation (Shoemaker et
al. 1998; Haigis et al. 2002, 2004; Haigis and Dove 2003). There-
fore, if the Mom2R mutation acted in a dominant fashion, its ac-
tion would be independent of whether it was located on the
same chromosome as the ApcMin allele. However, if the mecha-
nism of action were by LOH, then the mutant Atp5a1 allele
would only prevent polyps when it was on the same chromo-
some as the ApcMin mutation (in cis); elimination of both the
wild-type Apc and Atp5a1 genes on the wild-type homolog would
lead to cell death, since there would no longer be a functional
Atp5a1 gene.
One method to test this hypothesis is to determine polyp
number in mice where the Mom2R mutation resides on the same
chromosome as the ApcMin mutation (in cis) as opposed to the
Mom2R mutation and the ApcMin mutation residing on different
chromosome 18 homologs (in trans). Crosses were performed to
generate offspring with the Mom2R mutation in both the cis and
trans configurations with respect to the ApcMin mutation (Fig. 3).
Quantitation of the number of polyps was performed on progeny
aged for 150 d. Control mice that carried only the ApcMin muta-
tion developed an average of 88 polyps in the small intestine,
whereas those mice that carried ApcMin and Mom2R on the same
chromosome (in cis) developed a significantly lower average of
only six polyps (Student’s t-test, P < 0.0001); these data are con-
sistent with our previous findings for the Mom2R phenotype (Sil-
verman et al. 2002, 2003). However, mice that carried the ApcMin
and Mom2R mutations on different homologs (in trans) devel-
oped an average of 99 polyps, which is not significantly different
from the ApcMin-only control group (Student’s t-test, P > 0.5). The
results shown in Figure 3 clearly demonstrate that on a DBA
background, Mom2R functions as a potent suppressor of polyp
formation only when in cis with respect to the ApcMin muta-
tion.
Previous studies have shown that on a B6 background, pol-
yps that develop have not only lost their Apc+ allele, but have lost
the entire chromosome 18 (Shoemaker et al. 1998; Haigis and
Dove 2003; Haigis et al. 2004). We determined whether LOH for
Apc+ is occurring in adenomas from ApcMin/+ mice compared with
adenomas from ApcMin/+ Mom2R/+ mice (Fig. 4). The data clearly
show that the majority of adenomas (12/16) from ApcMin/+ mice
have lost their Apc+ allele, whereas only one adenoma (1/21)
from ApcMin/+ Mom2R/+ mice has lost its Apc+ allele (P < 107).
Histopathological analysis of the adenomas used in the LOH
analysis revealed that three of 21 tumors in ApcMin/+ Mom2R/+
mice progressed to carcinomas, whereas none of the adenomas in
ApcMin/+ mice progressed (Figs. 4, 5).
Effects of Mom2 on intestinal tumorigenesis
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Discussion
The observation that the Mom2R locus carried a recessive embry-
onic lethal mutation initially enabled the use of an exclusion
mapping technique to identify the Mom2 gene as well as to pro-
vide a testable hypothesis for Mom2R function. This strategy ex-
cludes any marker homozygous for the B6 allele within the Mom2
region as being a part of the Mom2 locus (Fig. 1). This exclusion
mapping technique should be applicable to any mutation that
results in embryonic lethality (Williams 1999). Our mapping re-
Figure 2. The coding region of the Atp5a1 gene contains a 4-bp insertion. (A) Results of the real-time PCR analysis of intestinal expression of Atp5a1
and 8030462N17Rik expression in B6, DBA, and DBA.Mom2R/+ congenic mice. A graphical representation of the relative expression levels of Atp5a1 and
8030462N17Rik in the proximal small intestine, distal small intestine, and colon are shown. Experimentally determined expression levels in wild-type
B6, wild-type DBA, and the Mom2R/+ congenic are shown. The predicted WT bar indicates the expected expression level in the Mom2R/+ congenic
animal, assuming 50% contribution from both parental alleles. Atp5a1 reproducibly demonstrated an expression of 50% of the DBA/2J allele, with no
contribution from the B6 allele. 8030462N17Rik was representative of the other genes that mapped to the congenic interval, demonstrating an
expression level equivalent to the predicted level (Supplemental Methods 1). (B) The sequence of exon 3 of the Atp5a1 gene in a Mom2R/+ mouse reveals
a divergence beginning after the 100th nucleotide of exon 3. The mutation is a 4-bp duplication of ATGG (shown in box) within exon 3. (C) The amino
acid sequence of the wild-type Atp5a1 gene is shown in comparison to the amino acid sequence of the mutant Atp5a1Mom2R allele. The 4-bp insertion
results in a frameshift that is predicted to generate a severely truncated protein.
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sults from the intersubspecific intercross, which utilized the phe-
notype of lethality, are consistent with the mapping results from
the B6 and DBA backcrosses, which utilized the phenotype of
polyp multiplicity (Silverman et al. 2003). While more than one
gene in the region could be affected, the simplest hypothesis is
that a spontaneous mutation in the Atp5a1 gene has a dominant
phenotype of polyp suppression and a recessive phenotype of
embryonic lethality. Understanding the biological function of
the Atp5a1 gene will provide important insights concerning its
potential role as a modifier of human cancer.
Embryonic lethality of the Mom2R mutation
The Mom2R allele is an early embryonic recessive lethal mutation.
In timed pregnancies, we were unable to recover homozygous
Mom2R embryos by 12.5 d of gestation. Since we propose that
Mom2R is a null allele for the Atp5a1 gene, leading to a nonfunc-
tional ATP synthase  subunit, it is not surprising that it is a
recessive lethal mutation. Silencing of the Atp5a1 gene in Try-
panosoma brucei and Trypanosoma evansi results in lethality
(Schnaufer et al. 2005). Mitochondrial synthesis dramatically in-
creases during early to late blastocyst stage, comprising up to 7%
of total protein synthesis in the embryo (Taylor and Piko 1995).
The energy need of developing embryos dramatically increases
during the formation of the blastocoel. Anoxic respiration is the
primary form of ATP production until implantation and the for-
mation of the placenta (Houghton et al. 1996). Aerobic respira-
tion increases during late blastocyst stage (Ginsberg and Hillman
1975). With the increasing demands for aerobic respiration and
energy needs during blastocoel formation and implantation, it is
likely that the homozygous Mom2R embryos die around this stage
of development due to their inability to produce sufficient en-
ergy for their needs.
The Atp5a1 gene and aerobic respiration
The Atp5a1 gene encodes the  subunit of the ATP synthase com-
plex, which is composed of 16 protein subunits (Boyer 1997).
Two of these subunits are encoded by
mitochondrial genes; the remainder are
encoded by nuclear genes. The as-
sembled complex, composed of the F0
and F1 subunits, is localized to the inner
mitochondrial membrane. The F0 com-
plex spans the membrane and is a hy-
drogen ion (H+) pump, while the F1
complex is a molecular motor harness-
ing the H+ gradient to produce ATP by
oxidative phosphorylation (Boyer 1997).
Atp5a1 is one of the five subunits (,  ,
, and ) comprising the F1 complex of
ATP synthase. The human ortholog
(ATP5A1) has been mapped to chromo-
some 18q12-q21 (Godbout et al. 1997).
Atp5a1 is encoded by 12 exons and at
least two splice variants have been de-
tected that differ in the 3 UTR (Yotov
and St-Arnaud 1993). Inherited muta-
tions affecting ATP synthase function
have mainly been identified in the mi-
tochondrial-encoded ATP6 gene, result-
ing in NARP (neuropathy, ataxia, and
retinitis pigmentosa) and a form of
Leigh syndrome (Nijtmans et al. 2001). A hypomorphic mutation
in a nuclear-encoded ATP synthase chaperone, ATPAF2 (formerly
known as ATP12), has been identified (De Meirleir et al. 2004).
We report here the first mutation identified in the Atp5a1 gene of
mice or humans.
The ATP5A1 gene and cancer
The ATP5A1 gene may provide a novel target to aid in diagnos-
tics, prevention, and/or treatment of cancer. Several studies have
identified an important link between the respiratory state of can-
cer cells and the tendency of those cells to be malignant. The
Warburg hypothesis originally proposed that cancer cells have
impaired mitochondrial function leading to an elevated rate of
glycolysis in tumor cells (Warburg 1956). While the identifica-
tion of the genetic basis of cancer has “ruled out” the causal
relationship between elevated levels of glycolysis and transfor-
mation, the basic tenet of the Warburg hypothesis has been dem-
onstrated in many tumor types (Cuezva et al. 2002, 2004). Stud-
ies have demonstrated a significant decrease in oxidative phos-
phorylation with an increase in glycolysis in cancer tissues. In
lung, liver, kidney, and colon carcinomas, a decrease in the ex-
pression of ATP5B has been observed (Cuezva et al. 2002, 2004).
This decrease in ATP synthase production is also associated with
resistance to chemo- and radiotherapies in several cancers. De-
creased expression of ATP5A1 has been detected in colon cancer
cells that exhibit resistance to 5-fluorouracil in culture; however,
the decrease in ATP5A1 levels may precede and contribute to the
ability of these colon cancer cells to attain resistance to 5-fluo-
rouracil (Shin et al. 2005).
In several studies, it has been demonstrated that resveratrol
inhibits adenoma development in ApcMin/+ mice (Schneider et al.
2001; Ziegler et al. 2004; Sale et al. 2005). Resveratrol is a phyto-
alexin found in grape skins that has diverse effects on cell cycle
control and is a cancer chemopreventative agent (Ulrich et al.
2005). One of its many biological effects is the binding and in-
hibition of the F1 subunit of ATP synthase, resulting in the inhi-
bition of ATP production (Zheng and Ramirez 2000). Alteration
Figure 3. The cis–trans test reveals that the Mom2R mutation functions only when in cis with the
ApcMin mutation. Two crosses were established to test whether Mom2R could function in trans as well
as in cis. Three mating cages of DBA.B6 Mom2R/+  DBA.B6 ApcMin/+ mice produced progeny that
carried only the ApcMin mutation on chromosome 18 (A) or progeny that carried the ApcMin mutation
on one chromosome 18 homolog and the Mom2R mutation on the other chromosome 18 homolog (C,
in trans). Three mating cages of DBA/2J  DBA.B6 ApcMin/+, Mom2R/+ mice produced progeny that
carried both the ApcMin and Mom2R mutations on the same chromosome 18 homolog (B, in cis). All
parents of these progeny were at the N9–N12 backcross generations. The chromosomes show the
positions of the Apc and Mom2 alleles on chromosome 18 homologs. Below the chromosomes is
shown the average number of polyps standard deviation. Statistical analyses showed that there is no
significant difference in polyp numbers between the control group carrying only the ApcMin allele and
the group that has ApcMin and Mom2R in trans. (A vs. C, P > 0.5). In contrast, the only progeny that
show highly significant differences with decreased polyp numbers is the ApcMin group that has Mom2R
in cis (B vs. A, P < 0.0001; B vs. C, P < 0.0001).
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of the mitochondrial membrane potential is one of the primary
responses to treatment by resveratrol (Sareen et al. 2006). It is
tempting to speculate that the mode of action of resveratrol is to
inhibit ApcMin adenoma formation through the inhibition of ATP
synthase in the intestinal stem cells. Therefore, in the presence of
resveratrol and after loss of the chromosome containing the Apc+
allele (along with an Atp5a1+ allele), there is insufficient ATP
synthesis, that results in a metabolic stress on the initiating tu-
mor cell resulting in cell death.
The decrease in ATP synthase activity in later stages of can-
cer is at odds with the finding that a mutation in Atp5a1 results
in a decrease of polyp multiplicity. However, this discrepancy
most likely reflects the differing energy requirements for early-
stage tumor initiation in contrast to later stages of cancer pro-
gression.
Mechanism of polyp suppression by the Mom2R mutation
The mechanism of polyp formation on a B6 genetic background
was originally proposed to result from loss of the entire chromo-
some containing the wild-type Apc allele (Levy et al. 1994;
Luongo et al. 1994; Shoemaker et al. 1998; Haigis et al. 2004).
However, current studies indicate that the loss of heterozygosity
of the Apc+ allele results primarily from somatic recombination,
with a small fraction of polyps exhibiting chromosomal homo-
zygosis (Haigis et al. 2002; Haigis and Dove 2003). These mecha-
nisms provide a working hypothesis for the Mom2R allele in
polyp protection. Inhibition of ATP synthase activity using oli-
gomycin has demonstrated that cells experiencing a 65%–85%
decrease in ATP synthase activity undergo apoptosis in vitro
(Comelli et al. 1998, 2003). Therefore, any mechanism resulting
in loss of both wild-type Atp5a1 alleles should cause cell death,
due to the absence of ATP synthase activity. Since the chromo-
some carrying the ApcMin allele also carries the mutant Atp5a1
allele, loss of the Apc+ Mom2+ chromosome 18 would result in
loss of the only functional Atp5a1 allele (Fig. 6A). Furthermore,
any stem cell in intestinal crypts that undergoes somatic recom-
bination and becomes homozygous for the ApcMin mutation
(which would normally lead to polyposis), would undergo cell
death in Mom2R/+ mice, due to the fact that the cell is now ho-
mozygous for the Atp5a1 mutation (Fig. 6B). Similarly, chromo-
somal homozygosis of the chromosome carrying both the ApcMin
and Atp5a1 mutations (cis configuration) would also result in cell
death (Fig. 6C). Thus, when the Mom2R allele is in cis with the
ApcMin mutation, LOH of the wild-type chromosome results in a
dramatic ∼90% reduction in polyp formation. It is interesting to
note that this degree of reduction in polyp numbers is compa-
rable and consistent with the decrease in polyp numbers seen
in ApcMin mice carrying the Robertsonian translocation
Rb(7.18)9Lub, which has been shown to suppress somatic recom-
bination in ApcMin mice (Haigis and Dove 2003).
How do the few polyps arise in ApcMin/+, Mom2R/+ mice?
The finding of a few polyps in some mice that carry ApcMin and
Mom2R in cis suggested several mechanisms by which intestinal
cells can escape polyp suppression (Fig. 6). The data indicate that
the few polyps that form in Mom2R/+ animals maintain hetero-
zygosity for both Apc alleles (Fig. 4). Therefore, since the wild-
type chromosome 18 is retained, the Apc+ allele must be inacti-
vated. This event could occur by either epigenetic silencing (Es-
teller et al. 2000; Chen et al. 2005) or somatic mutation (Miyaki
Figure 4. Quantitation of the Apc+:ApcMin ratio in normal and adenoma tissues in Mom2R/+ mice. Paraffin-embedded polyp and normal tissues were
microdissected from slides. DNA was isolated using Qiagen DNeasy Tissue Kit. Genomic DNA was genotyped for the ApcMin mutation, PCR products run
on a 4% agarose gel, and scanned using an EtBr filter on a Typhoon scanner. Ratios were quantified using ImageQuant 5.2. Values reflect the average
of duplicate trials. Black bars represent normal tissue; turquoise bars represent polyps from B6 ApcMin/+, Mom2+/+ mice (aged ∼4–5 mo); salmon bars
represent polyps from B6 ApcMin/+, Mom2R/+ mice (aged ∼15–17 mo). Hatched bars represent tumors that progressed to carcinomas. A ratio of 1.0 (red
line) represents the ideal Mendelian 1:1 ratio of Apc+:ApcMin alleles expected in genomic DNA from a normal heterozygote. Ratios below 0.5 suggest
loss of the Apc+ allele, whereas ratios above 1.5 suggest loss of the ApcMin allele. The ratios of normal tissue from ApcMin/+, Mom2+/+ mice (1.56  0.62)
do not appear to vary from the ratios of normal tissue from ApcMin/+, Mom2R/+ mice (1.46  0.15) (P > 0.6, t-test). Interestingly, comparison of the ratios
of tumor (1.38  0.35) to normal (1.46  0.15) tissues from ApcMin/+, Mom2R/+ mice indicate that they are quite similar (P > 0.5, t-test), suggesting that
most tumors from ApcMin/+, Mom2R/+ mice retain both Apc alleles. In contrast, comparison of the ratios of tumor (0.54  0.41) to normal (1.56  0.62)
tissues from ApcMin/+, Mom2+/+ mice show a striking difference (P < 2  104, t-test), suggesting that most polyps lose the Apc+ allele. Furthermore, the
ratios of tumor tissue from ApcMin/+, Mom2+/+ mice (0.54  0.41) differ significantly from the ratios of tumor tissue from ApcMin/+, Mom2R/+ mice
(1.38  0.35) (P < 3  107, t-test). These data indicate that most tumors in ApcMin/+, Mom2R/+ mice arise by a mechanism different from that
occurring in ApcMin/+, Mom2+/+ mice.
Baran et al.
572 Genome Research
www.genome.org
 Cold Spring Harbor Laboratory Press on March 8, 2012 - Published by genome.cshlp.orgDownloaded from 
et al. 1995; Crabtree et al. 2003) of the Apc+ allele. Alternatively,
somatic recombination could occur between the ApcMin and
Mom2R mutations, resulting in a chromosome that has only the
ApcMin mutation and a wild-type Atp5a1 allele. Chromosomal
homozygosis (Haigis et al. 2002, 2004) and/or loss of the recip-
rocal recombinant would result in a cell that carries only the
ApcMin mutation and the Atp5a1+ gene, thus resulting in a polyp
(Fig. 6D–F).
Several features of the adenomas that develop in ApcMin/+
Mom2R/+ mice are reminiscent of human tumorigenesis. The
most common mechanisms of LOH for the APC gene involve: (1)
epigenetic silencing, (2) base substitutions within the coding re-
gion, or (3) small intragenic deletions (Fearnhead et al. 2001).
However, human colon tumors have not been shown to lose the
entire chromosome carrying the APC gene, as has been demon-
strated for chromosome 18 in B6 ApcMin/+ mice (Levy et al.
1994; Luongo et al. 1994). Therefore, retention of the Apc+ allele
in polyps from ApcMin/+ Mom2R/+ mice is one feature that
accurately recapitulates human tumorigenesis. In addition,
the heavy polyp load in B6 ApcMin/+ mice usually leads to
death by 5–6 mo of age, and adenomas in these mice rarely
progress to carcinomas (Halberg et al. 2000; Cooper et al. 2005).
In contrast, the light polyp load in ApcMin/+ Mom2R/+ mice allows
for a significantly longer lifespan (>2 yr) and ∼15% of adenomas
progress to carcinomas by 15–17 mo of age (Figs. 4, 5). Whether
progression is related to the longer lifespan or, alternatively, to
the retention of the Apc+ chromosome, remains to be deter-
mined. Regardless of the mechanism, ApcMin/+ Mom2R/+ mice pro-
vide informative vehicles to test therapeutic agents designed to
prevent tumor progression.
Generation of congenic mice and the chance for any mutation
on mouse chromosome 18 to result in a similar phenotype
for Min
Our identification of a recessive lethal mutation that is physically
linked to the ApcMin mutation suggests that a recessive cell-lethal
mutation in any gene on mouse chromosome 18 would re-
sult in a reduction in the number of intestinal polyps (if it
resided in cis with the ApcMin mutation). This statement would
be true in any mouse strains (such as B6) in which the major
mechanism of Apc+ inactivation involved loss of the chro-
mosome carrying the Apc+ allele. In addition, continued
selection for a specific mutation or chromosomal region (such
as occurs during the derivation of congenic lines) may in-
crease the chances of such mutations becoming fixed within a
colony. The Mom2R mutation may have been perpetuated within
the ApcMin colony at The Jackson Laboratory, because the mice
that carried Mom2R would have appeared more fit, had higher
reproductive capacity, and lived longer than their susceptible
Mom2+ littermates. Such mutations, if providing a selective ad-
vantage, could eventually become the predominant allele within
a colony, thus altering the characteristics of the inbred strain
over time.
Potential examples of other such mutations occurring on
the ApcMin chromosome are suggested in the literature. For ex-
ample, Wilson et al. (1997) reported that B6 ApcMin/+ mice devel-
oped an average of 25.4 polyps (range 20–38 polyps) when aged
for 120 d (Wilson et al. 1997); a later publication using the same
Min colony showed an average tumor number of only 18 polyps
(Wagenaar-Miller et al. 2003). Similarly, Javid et al. (2005) re-
ported an average of 18.9  6.8 (SD) polyps in C57BL/6J ApcMin
mice obtained directly from The Jackson Laboratory. These num-
bers are substantially smaller and have a much lower variance
than the number of polyps commonly reported for B6 ApcMin/+
mice (Siracusa et al. 2004). These almost uniform types of polyp
distributions suggest that other loci tightly linked to the ApcMin
mutation are responsible for resistance to polyp formation. In
contrast, a recent report has identified a novel modifier closely
linked to ApcMin that results in a dramatic increase in polyp mul-
tiplicity that arose during selective inbreeding of a hybrid strain
(Haines et al. 2005).
Several publications that describe polyp multiplicity in
ApcMin mice on a C57BL/6J (or congenic) background de-
monstrate that there exists much variation in polyp multiplicity
(Song et al. 2000; Tucker et al. 2002; Mai et al. 2003; Haines
et al. 2005; Moran et al. 2005). While some of this variation
might be explained by environmental differences, it is clear
from our studies that heterogeneity exists within inbred strains
of mice, and could be due to the presence of spontaneous
mutations that alter the genetic “homogeneity” of a model sys-
tem.
Figure 5. Polyps from B6 ApcMin/+, Mom2R/+ mice tend to be more
advanced than polyps from B6 ApcMin/+ mice. Microdissected polyps
were stained with hematoxylin and eosin and photographed on a
Nikon Eclipse E600 microscope at 100 magnification. (A,C,E,G,I)
Isolated from B6 ApcMin/+ Mom2+/+ mice as indicated. (B,D,F,H,J) Iso-
lated from B6 ApcMin/+ Mom2R/+ mice as indicated. Size measurements
revealed that adenomas in ApcMin/+ Mom2R/+ mice were threefold larger
than the adenomas in ApcMin/+ Mom2+/+mice (P = 0.03) (data not
shown).
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Methods
Mice
Mice were bred at the AAALAC-accredited TJU Animal Facility,
except for the original C57BL/6J (B6) ApcMin/+ males, DBA/2J
(DBA) mice, and CAST/Ei (CAST) mice, which were purchased
from The Jackson Laboratory. Animals were fed laboratory auto-
clavable rodent diet 5010 (PMI Nutrition International, Inc.).
Special husbandry protocols were followed to ensure both repro-
ductive fecundity and viability of CAST mice; these mice were
housed in a designated “quiet room” in large microisolator cages
with specially designed lids to prevent escape. Cages were pre-
pared with autoclaved aspen shavings, 2–3 nestlets, food, and
water bottles.
Genomic DNA isolation and sequencing
Genomic DNA was isolated from tail biopsies as described (Sil-
verman et al. 2002). Genomic DNA from organs was isolated
using a standard phenol-chloroform method and resuspended in
water (Sambrook and Russell 2001). Genomic DNA was subjected
to PCR using primer pairs derived from intronic sequences de-
signed to amplify exons of Atp5a1, Ccdc5, and Pstpip2 (Supple-
mental Tables 2, 3, 4). Resulting fragments were purified and
sequenced with a 377-DNA Sequencer from ABI Prism by the
KCC Nucleic Acids Facility. Sequencing was performed using both
forward and reverse primers and the resulting sequences were
aligned using BLAST (http://www.ncbi.nlm.nih.gov/BLAST/).
DBA.B6 Mom2R/+ intercross
Congenic mice were generated through selection and backcross-
ing of DBA.B6 ApcMin/+, Mom2R/+ N# mice with DBA animals;
offspring were genotyped by PCR for the ApcMin mutation as well
as for the Mom2 locus using the flanking markers D18Mit186 and
D18Mit213 (Silverman et al. 2003). Progeny were selected that
carried the Mom2-resistant region (Mom2R/+), but did not carry
the ApcMin mutation. DBA.B6 Mom2R/+ animals from the N4–N5
backcross generations were intercrossed to generate Mom2R/R ho-
mozygotes. Each F2 offspring was genotyped for the Mom2 region
by PCR with D18Mit80 and D18Mit213 as described (Silverman
et al. 2003), and to determine whether they were Mom2R/R,
Mom2R/+, or Mom2+/+. Four offspring that showed recombination
within the Mom2 region were not informative and were therefore
excluded from the analyses (data not shown).
Genotyping for molecular markers
The ApcMin mutation was genotyped by modification of a previ-
ously published protocol (Luongo et al. 1994) as described (Sil-
verman et al. 2003). SSLP markers were selected based on poly-
morphisms that were identified between the B6 and CAST
strains. Primer pairs were purchased from Invitrogen. A total of
50–100 ng of genomic tail DNA was amplified along with 50 ng
each of the oligomers, 0.5 mM of each nucleotide (dCTP, dGTP,
dTTP, and dATP), in a buffer (final concentration 50 mM KCl, 10
mM Tris-HCl at pH 8.0, 1.5 mM MgCl2, and 0.1 mg/mL gelatin),
along with 5 U/µL of Taq DNA polymerase (Roche Molecular
Figure 6. Mechanism of Mom2R suppression of ApcMin-induced polyposis. The chromosome 18 homologs present in an ApcMin/+ Atp5a1+/ mouse are
shown. Previous work has shown that in the B6 mouse, the major mechanism of polyp formation involves loss of the entire wild-type chromosome 18
(A). If this occurs, a cell would lose its wild-type Atp5a1+ allele and die. Similarly, if somatic recombination distal to Apc (B) or chromosomal homozygosis
(C) of the ApcMin Atp5a1 chromosome occurs, the cell would have no wild-type Atp5a1+ allele and die. Therefore, these mechanisms would prevent
stem cells from developing into polyps. However, if both chromosome 18 homologs remain (D), polyps could develop in cells that have their wild-type
Apc allele silenced or inactivated. In this case, a cell would retain its wild-type Atp5a1+ allele. Similarly, recombination between the Apc and Atp5a1 loci
could occur, followed by loss of the chromosome containing the Apc+ and Atp5a1 alleles (F) or nondisjunction (E). In these cases, cells retaining the
mutant ApcMin allele and the wild-type Atp5a1+ allele could form polyps.
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Biochemicals). Samples were amplified under the following con-
ditions: one cycle at 94°C for 4 min, followed by 35 cycles at 94°C
for 30 sec, 58°C or 60°C for 45 sec, 72°C for 30 sec, and ending
with one cycle at 72°C for 7 min. Polymorphisms of 10 bp or
higher were detected on 3% TBE agarose gels and visualized by
staining with EtBr (Sambrook and Russell 2001). If the polymor-
phism was <10 bp, the forward primer was end-labeled with
[32P]dATP using polynucleotide kinase prior to PCR (Sambrook
and Russell 2001); 6% denaturing polyacrylamide urea gels were
used for resolution of the radiolabeled products, followed by au-
toradiography (Sambrook and Russell 2001).
Identification of new SSLP markers
Candidate SSR marker primer pairs were generated using the
Mouse Genome SSR search website, Massachusetts General Hos-
pital (Charlestown, MA; http://danio.mgh.harvard.edu/
mouseMarkers/musssr.html). Several primer pairs (D18Kcc# loci)
in the Mom2 region detected polymorphisms between B6, DBA,
and CAST mice (Supplemental Table 1).
Genotyping for the mutation in the Atp5a1 gene
The mutation in the Atp5a1 gene was detected by designing
primers that incorporated the 4-bp insertion into the sequence.
The forward primer (5-GTTAAGCATTGGTGATGGATGG-3) lies
at the site of the insertion (middle of exon 3) and will only bind
the mutant Atp5a1 allele. The reverse primer (5-TGAGA
GAGCAAAGCTACAGATCC-3) lies within intron 3. PCR reac-
tions contained 100 ng of genomic DNA, 50 ng each of the for-
ward and reverse oligomers, 0.5 mM of each nucleotide (dCTP,
dGTP, dTTP, and dATP), in a buffer (final concentration 50 mM
KCl, 10 mM Tris-HCl at pH 8.0, 1.5 mM MgCl2, and 0.1 mg/mL
gelatin), along with 5 U/µL of Taq DNA polymerase (Roche Mo-
lecular Biochemicals). Samples were amplified under the follow-
ing conditions: one cycle at 94°C for 4 min, followed by 35 cycles
at 94°C for 45 sec, 60°C for 45 sec, 72°C for 45 sec, ending with
one cycle at 72°C for 7 min. A 147-bp fragment was detected
when the mutant Atp5a1 allele was present, whereas no fragment
was detected in mice homozygous for the wild-type Atp5a1 gene.
Assessment of intestinal polyp number in ApcMin mice
ApcMin/+ mice generated from crosses of DBA  DBA.B6 ApcMin/+
mice were aged and then euthanized by CO2 asphyxiation. The
small intestine and colon were dissected and cleared of residual
debris as described (Koratkar et al. 2002, 2004). Polyps were
counted using a Nikon SMZ-U dissection scope at 15 magnifi-
cation.
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